[B-lymphocytes as effectors and regulators in systemic lupus erythematosus].
Nikolaus-Fiebiger-Zentrum für Molekulare Medizin, Lehrstuhl Genetik, Friedrich-Alexander Universität Erlangen-Nürnberg, Glückstr. 6, 91054, Erlangen, Deutschland, thomas.winkler@fau.de.
T H
TH
Winkler
D000818:Animals; D000974:Antibodies, Antinuclear / Q000097:blood; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D017951:Antigen Presentation / Q000187:drug effects / Q000276:immunology; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood; D016175:B-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology*; D060151:B-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology*; D016207:Cytokines / Q000097:blood; D004195:Disease Models, Animal; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D007678:Kidney Glomerulus / Q000187:drug effects / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology*; D008181:Lupus Nephritis / Q000188:drug therapy / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D051379:Mice; D010950:Plasma Cells / Q000187:drug effects / Q000276:immunology; D000069283:Rituximab
D000974:Antibodies, Antinuclear; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D001323:Autoantibodies; D016207:Cytokines; D016753:Interleukin-10; D000069283:Rituximab; C511911:belimumab